STOCK TITAN
  1. Home
  2. News
  3. SCYX

SCYNEXIS, Inc. - SCYX STOCK NEWS

Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a front-running pharmaceutical company dedicated to discovering, developing, and commercializing novel anti-infectives. Based in Jersey City, SCYNEXIS aims to address significant unmet therapeutic needs, particularly in the realm of fungal infections. Their primary product candidate, ibrexafungerp, is an innovative oral and intravenous drug targeting a wide range of serious and life-threatening invasive fungal infections.

SCYNEXIS is renowned for its groundbreaking antifungal platform known as “fungerps.” Ibrexafungerp, the first representative of this class, received FDA approval for treating vulvovaginal candidiasis (VVC) and for reducing the incidence of recurrent VVC. This compound is also in late-stage clinical trials targeting invasive fungal infections in hospitalized patients. SCYNEXIS is continuously advancing its pipeline with new antifungal candidates like SCY-247, which has shown promising preclinical results against multiple drug-resistant fungal pathogens.

In recent developments, SCYNEXIS voluntarily recalled two lots of BREXAFEMME® due to potential cross-contamination with a non-antibacterial beta-lactam substance. Although no adverse events have been reported, the company is taking proactive measures to address the issue and ensure consumer safety. Meanwhile, SCYNEXIS continues to make strides in research and development, with significant investments aimed at expanding their antifungal arsenal.

For more information about SCYNEXIS, Inc., including their latest news and updates, visit www.scynexis.com.

News

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
SCYNEXIS, Inc. (SCYX) reports positive financial results for 2023, with significant progress in developing SCY-247 and advancing clinical studies. The company ended 2023 with $98.0 million in cash and projects a cash runway of over two years. Phase I initiation for SCY-247 is expected in the second half of 2024, with promising preclinical results against fungal pathogens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
earnings
-
News

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Rhea-AI Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that David Angulo, M.D., President and CEO, will present at Guggenheim’s 6th Annual Biotechnology Conference on February 7, 2024. The conference will include a fireside chat and one-on-one meetings, and will be held in New York, NY. The webcast link will be available for those who cannot attend in person.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
News

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Rhea-AI Summary
SCYNEXIS, Inc. presents preclinical efficacy data on SCY-247, a second-generation fungerp candidate showing promising results in treating mucormycosis. The oral SCY-247 demonstrated a response rate similar to the current standard of care, Liposomal Amphotericin B, and when combined with LAMB, it resulted in a significant enhancement in survival and reduction in fungal burden in lung and brain tissue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
News

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Rhea-AI Summary
SCYNEXIS, a biotechnology company (NASDAQ: SCYX), announced preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference. The study showed SCY-247's in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. The combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy. The study was funded by the National Institutes of Health (NIH) utilizing the National Institute of Allergy and Infectious Diseases suite of preclinical services for in vivo testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
conferences clinical trial
-
News

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) reported financial results for Q3 2023, highlighting the progress of their next generation antifungal drug, SCY-247, and the evaluation of remediation strategies following the voluntary recall of BREXAFEMME® and the clinical hold on the MARIO trial. The company's cash position of $105.2 million provides a cash runway of over two years. SCYNEXIS also provided updates on the ibrexafungerp clinical and regulatory status, NMPA acceptance for review in China, and the preclinical development program for SCY-247. Financially, the company recognized a loss of ($0.6) million in product revenue and a net loss of $1.8 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
-
News

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Rhea-AI Summary
SCYNEXIS presents preclinical data on second-generation antifungal candidate SCY-247 at medical mycology conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
clinical trial
News

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

Rhea-AI Summary
SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) due to potential cross contamination with a non-antibacterial ß-lactam drug substance, posing a risk of hypersensitivity reactions. No adverse events reported. The recalled lots were distributed nationwide. Consumers should contact their healthcare provider for any related issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
-
News

SCYNEXIS to Participate in September Investor Conferences

Rhea-AI Summary
SCYNEXIS, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
conferences
-
News

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
SCYNEXIS reported closing of exclusive license agreement with GSK for BREXAFEMME. Received $90M upfront payment and $25M milestone payment. NDA for oral ibrexafungerp tablets accepted in China. Cash balance of $91.9M with projected cash runway beyond two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
earnings
News

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

Rhea-AI Summary
SCYNEXIS, Inc. announced that China’s NMPA has accepted for review a New Drug Application for oral ibrexafungerp tablets for the treatment of vulvovaginal candidiasis in China. The application is based on positive Phase 3 study results, and if approved, ibrexafungerp will be a new anti-fungal treatment for Chinese patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none

FAQ

What is the current stock price of SCYNEXIS (SCYX)?

The current stock price of SCYNEXIS (SCYX) is $1.09 as of February 4, 2025.

What is the market cap of SCYNEXIS (SCYX)?

The market cap of SCYNEXIS (SCYX) is approximately 41.3M.

What does SCYNEXIS, Inc. specialize in?

SCYNEXIS specializes in discovering, developing, and commercializing novel anti-infective drugs, particularly for treating serious fungal infections.

What is ibrexafungerp?

Ibrexafungerp is SCYNEXIS's lead product candidate, a novel oral and intravenous drug for treating serious and life-threatening fungal infections.

What recent achievements has SCYNEXIS made?

SCYNEXIS recently presented promising preclinical data on its second-generation antifungal candidate, SCY-247. They also received FDA approval for ibrexafungerp to treat VVC and reduce recurrent VVC.

Why did SCYNEXIS recall BREXAFEMME®?

SCYNEXIS voluntarily recalled two lots of BREXAFEMME® due to potential cross-contamination with a non-antibacterial beta-lactam substance.

What is SCY-247?

SCY-247 is a second-generation antifungal candidate under development at SCYNEXIS, showing efficacy against multiple drug-resistant fungal pathogens in preclinical studies.

How does SCYNEXIS contribute to treating drug-resistant infections?

SCYNEXIS is pioneering innovative medicines like ibrexafungerp and SCY-247 to treat and prevent difficult-to-treat and drug-resistant fungal infections.

Who can I contact for more information about SCYNEXIS?

For more information, you can contact Irina Koffler, Investor Relations at LifeSci Advisors, via email at ikoffler@lifesciadvisors.com or phone at (646) 970-4681.

What are the financial highlights of SCYNEXIS?

For Q2 2023, SCYNEXIS reported research and development expenses of $7.0 million, compared to $7.1 million for Q2 2022.

Where is SCYNEXIS headquartered?

SCYNEXIS is headquartered in Jersey City, New Jersey.

How can I report adverse reactions to SCYNEXIS products?

Adverse reactions can be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail, or by fax.
Stock SCYX logo
SCYNEXIS, Inc.

Nasdaq:SCYX

SCYX Rankings

#5010 Ranked by Market Cap
N/A Ranked by Dividends

SCYX Stock Data

41.25M
37.04M
1.17%
42.36%
2.23%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
JERSEY CITY